Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Monograph Application Reviews Get Deadlines, Not GRASE Flexibility

Executive Summary

Changes to FDA's interpretation of the GRASE standard it uses to evaluate ingredient proposals would go further to opening the US monograph process to innovation and progress than setting deadlines for the reviews, industry stakeholders say.

You may also be interested in...



OTC Monograph Reform Proposal Offers Two-Tier Approach

One tier could provide two-year exclusivity, should FDA request clinical trials for new conditions or ingredients, under a US Senate discussion draft. Essentially stalled monograph process would be replaced by deadlines for FDA action in under two years.

Hawaii's Proposed Oxybenzone Sunscreen Ban Fails Science Test – CHPA

CHPA commits to fighting against onslaught of bills in Hawaii aiming to ban or limit the use of oxybenzone-containing sunscreens, says CEO and President Scott Melville during his address on 2017 priorities during the CHPA Annual Executive Conference in Amelia Island, Fla. March 21.

Hawaii's Proposed Oxybenzone Sunscreen Ban Fails Science Test – CHPA

CHPA commits to fighting against onslaught of bills in Hawaii aiming to ban or limit the use of oxybenzone-containing sunscreens, says CEO and President Scott Melville during his address on 2017 priorities during the CHPA Annual Executive Conference in Amelia Island, Fla. March 21.

Related Content

Topics

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel